KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2023 - 2025)

Biocryst Pharmaceuticals' EBITDA Margin history spans 9 years, with the latest figure at 34568.22% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 3458963.0% year-over-year to 34568.22%; the TTM value through Dec 2025 reached 56.07%, up 7589.0%, while the annual FY2025 figure was 30.06%, 4987.0% up from the prior year.
  • EBITDA Margin reached 34568.22% in Q4 2025 per BCRX's latest filing, up from 7.78% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34568.22% in Q4 2025 to a low of 61.65% in Q4 2023.
  • Average EBITDA Margin over 3 years is 3826.16%, with a median of 10.5% recorded in 2024.
  • The largest YoY upside for EBITDA Margin was 3458963bps in 2025 against a maximum downside of 1522bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 61.65% in 2023, then skyrocketed by 65bps to 21.41% in 2024, then skyrocketed by 161526bps to 34568.22% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EBITDA Margin are 34568.22% (Q4 2025), 7.78% (Q3 2025), and 3.43% (Q2 2025).